** Shares of drugmaker EyePoint Pharmaceuticals EYPT.O rise ~11% to $8.47
** EYPT says its drug, Duravyu, met the main goal in mid-stage trial for the treatment of diabetic macular edema, a condition where fluid builds up in the central part of the retina due to damaged blood vessels
** The main goal was to evaluate if the drug could reduce the frequency of injections needed to treat the condition compared to the standard treatment, aflibercept
** 2.7 mg dose of Duravyu helped 73% of patients avoid extra injections, compared to 50% of patients treated with aflibercept - EYPT
** Co plans to initiate a late-stage non-inferiority trial for the drug by the end of 2025
** EYPT fell ~67% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。